Recommendations for Epstein-Barr virus–based screening for nasopharyngeal cancer in high- and intermediate-risk regions. (1st February 2023)

• Record Type: Journal Article
• Authors: Lam, W K Jacky; King, Ann D; Miller, Jacob A; Liu, Zhiwei; Yu, Kelly J; Chua, Melvin L K; Ma, Brigette B Y; Chen, Ming Yuan; Pinsky, Benjamin A; Lou, Pei-Jen; Woo, John K S; Hsu, Wan-Lun; Simon, Julia; Doolan, Denise L; Waterboer, Tim; Hui, Edwin P; Li, Hui; Tsang, Raymond K; Wong, Kenneth C W; Goh, Julian P; Vlantis, Alexander C; Ai, Qi Yong; Wong, Lun M; Abdullah, Victor; Lin, Jin Ching; Chen, Chien-Jen; Pfeiffer, Ruth M; Le, Quynh-Thu; Lee, Anne W M; Ji, Mingfang; Cao, Sumei; Ma, Jun; Chan, Anthony T C; Chan, K C Allen; Hildesheim, Allan;
• Is Part Of: Journal of the National Cancer Institute. Volume 115:Number 4(2023)
• Page Start: 355
• Page End: 364
• Publication Date: 2023-02-01
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djad012
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: A meeting of experts was held in November 2021 to review and discuss available data on performance of Epstein-Barr virus (EBV)–based approaches to screen for early stage nasopharyngeal carcinoma (NPC) and methods for the investigation and management of screen-positive individuals. Serum EBV antibody and plasma EBV DNA testing methods were considered. Both approaches were found to have favorable performance characteristics and to be cost-effective in high-risk populations. In addition to endoscopy, use of magnetic resonance imaging (MRI) to investigate screen-positive individuals was found to increase the sensitivity of NPC detection with minimal impact on cost-effectiveness of the screening program.